MOA Life Plus Past Earnings Performance
Past criteria checks 0/6
MOA Life Plus has been growing earnings at an average annual rate of 31.7%, while the Biotechs industry saw earnings growing at 1.6% annually. Revenues have been declining at an average rate of 27.8% per year.
Key information
31.7%
Earnings growth rate
40.7%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -27.8% |
| Return on equity | -18.6% |
| Net Margin | -65.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Health Check: How Prudently Does MOA Life Plus (KOSDAQ:142760) Use Debt?
Oct 18
There's No Escaping Bioleaders Corporation's (KOSDAQ:142760) Muted Revenues Despite A 30% Share Price Rise
Apr 19Bioleaders Corporation's (KOSDAQ:142760) Business And Shares Still Trailing The Industry
Mar 01Bioleaders' (KOSDAQ:142760) Shareholders Are Down 47% On Their Shares
Feb 16
Revenue & Expenses Breakdown
How MOA Life Plus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 18,436 | -12,013 | 7,124 | 1,257 |
| 31 Mar 24 | 18,548 | -8,922 | 7,977 | 1,600 |
| 31 Dec 23 | 18,245 | -6,204 | 7,918 | 1,809 |
| 30 Sep 23 | -10,647 | 10,429 | -120 | 2,045 |
| 30 Jun 23 | -16,110 | 9,543 | -906 | 3,100 |
| 31 Mar 23 | 1,909 | -205 | 4,864 | 3,451 |
| 31 Dec 22 | 22,004 | -2,468 | 11,470 | 3,856 |
| 30 Sep 22 | 104,738 | -26,148 | 34,108 | 4,567 |
| 30 Jun 22 | 99,393 | -21,284 | 35,120 | 4,007 |
| 31 Mar 22 | 100,298 | -19,159 | 34,330 | 4,409 |
| 31 Dec 21 | 101,170 | -19,768 | 31,389 | 4,481 |
| 30 Sep 21 | 98,814 | -15,688 | 28,713 | 3,781 |
| 30 Jun 21 | 92,955 | -23,184 | 26,284 | 4,133 |
| 31 Mar 21 | 85,999 | -21,778 | 25,565 | 3,673 |
| 31 Dec 20 | 80,453 | -21,138 | 26,911 | 3,419 |
| 30 Sep 20 | 67,761 | -24,862 | 33,167 | 3,388 |
| 30 Jun 20 | 66,300 | -22,324 | 33,533 | 2,996 |
| 31 Mar 20 | 67,138 | -27,900 | 34,243 | 2,783 |
| 31 Dec 19 | 72,877 | -28,046 | 35,841 | 2,645 |
| 30 Sep 19 | 87,455 | -24,525 | 29,656 | 2,817 |
| 30 Jun 19 | 98,845 | -23,279 | 33,559 | 2,464 |
| 31 Mar 19 | 107,313 | -17,111 | 35,797 | 2,555 |
| 31 Dec 18 | 86,067 | -17,228 | 29,252 | 2,552 |
| 30 Sep 18 | 62,205 | -9,137 | 22,286 | 2,504 |
| 30 Jun 18 | 34,764 | -8,118 | 12,871 | 2,670 |
| 31 Mar 18 | 11,497 | -7,829 | 5,045 | 2,707 |
| 31 Dec 17 | 7,607 | -6,647 | 4,267 | 2,739 |
| 31 Dec 16 | 2,501 | -5,896 | 3,438 | 2,820 |
Quality Earnings: A142760 is currently unprofitable.
Growing Profit Margin: A142760 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A142760 is unprofitable, but has reduced losses over the past 5 years at a rate of 31.7% per year.
Accelerating Growth: Unable to compare A142760's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A142760 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: A142760 has a negative Return on Equity (-18.58%), as it is currently unprofitable.